- Home
- ESTC vs ACLX Comparison
ESTC vs ACLX Comparison
Compare ESTC & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESTC | ACLX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 6.7B |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ESTC | ACLX |
|---|---|---|
| Price | $47.49 | $115.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 27 | 15 |
| Target Price | $94.08 | ★ $115.85 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,483,296,000.00 | $22,286,000.00 |
| Revenue This Year | $19.06 | $411.22 |
| Revenue Next Year | $13.42 | $138.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $42.05 | $47.86 |
| 52 Week High | $96.07 | $115.10 |
Technical Indicators
Market Signals| Indicator | ESTC | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 81.33 |
| Support Level | N/A | $66.06 |
| Resistance Level | $51.91 | N/A |
| Average True Range (ATR) | 2.45 | 0.15 |
| MACD | 0.07 | -0.96 |
| Stochastic Oscillator | 53.45 | 88.39 |
Price Performance
Historical ComparisonAbout ESTC Elastic N.V.
Elastic is a software company that specializes in AI-search, observability, and security deployments. Its search division offers both traditional keyword search and vector search methods to enable more context-aware querying. The software has open-source origins but generates revenue through valuable add-ons, including simplified data orchestration and server scaling techniques.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.